Gemcitabine combined with docetaxel in metastatic breast cancer

Semin Oncol. 2003 Apr;30(2 Suppl 3):15-8. doi: 10.1053/sonc.2003.37270.


The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resistant patients, response rates have ranged from 36% to 54%, with median times to disease progression of 7 to 8 months and median survival of 12.7 to 14 months. In less treatment-experienced patients, the combination produced an overall response rate of 79%, median time to progression of 7.6 months, and median survival of 24.5 months. Toxicity has primarily consisted of neutropenia. The combination warrants additional investigation as front-line chemotherapy and in patients with anthracycline-resistant and taxane-resistant advanced disease.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Clinical Trials, Phase II as Topic
  • Deoxycytidine / administration & dosage*
  • Deoxycytidine / analogs & derivatives*
  • Docetaxel
  • Humans
  • Neoplasm Metastasis
  • Paclitaxel / administration & dosage*
  • Paclitaxel / analogs & derivatives*
  • Taxoids*


  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • gemcitabine
  • Paclitaxel